See the source article by following the link below:
Cardiovascular disease is the leading cause of death and complications in patients with type 2 diabetes. A new clinical trial reveals once weekly injection of a GLP1 analogue reduces this risk by 26%.
Cardiovascular disease is the leading cause of death and complications in patients with type 2 diabetes. A new clinical trial reveals once weekly injection of a GLP1 analogue reduces this risk by 26%.
No comments:
Post a Comment